The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes of a trial of the ECOG-ACRIN Cancer Research Group (E3204).
 
Jerome Carl Landry
No Relationships to Disclose
 
Yang Feng
No Relationships to Disclose
 
Roshan Sudhir Prabhu
No Relationships to Disclose
 
Steven J. Cohen
Consulting or Advisory Role - Bayer; Taiho Pharmaceutical
 
Charles A. Staley
No Relationships to Disclose
 
Richard M. Whittington
No Relationships to Disclose
 
Elin R. Sigurdson
No Relationships to Disclose
 
Halla Sayed Nimeiri
Honoraria - Genentech
 
Udit N. Verma
No Relationships to Disclose
 
Al Bowen Benson
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone; Merck Serono; Merck/Schering Plough; Sanofi; Spectrum Pharmaceuticals
Research Funding - advanced accelerator applications; Amgen; Astellas Pharma; Bayer/Onyx; Genentech (I); Gilead Sciences; Novartis
Travel, Accommodations, Expenses - Bayer; Genentech/Roche; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals